

## **Gambro and Dipylon Medical sign exclusive collaboration agreement**

**Gambro and Dipylon Medical AB (Dipylon), a Swedish medical device company with focus on cardiac monitoring, have signed an exclusive supply and development agreement. Through the agreement, Dipylon is granted exclusive rights to Gambro's advanced membrane technology for use in its diagnostic catheters intended for cardiac monitoring.**

The Dipylon Cardiac Catheter system enables early detection of potentially life-threatening ischemic complications following heart surgery. "Gambro is very excited to co-operate with Dipylon in developing their cardiac monitoring system. The collaboration offers Gambro the opportunity to leverage its leading membrane technology know-how into new diagnostic and therapeutic application areas." says Patrick Greatrex, Vice President Business Development at Gambro.

Heart disease is by far the most common cause of death in the Western World. Globally, nearly two million heart surgeries are performed each year. 30,000 of these patients will die from ischemic complications following surgery and there is today no reliable method to detect these complications. "Gambro's world-leading expertise in membrane technology has been instrumental in the development of our unique system. The collaboration has enabled us to launch the system, celebrate our first export success and raise additional growth capital financing to enable full commercialization." says Måns Alfvén, CEO of Dipylon.

The system consists of a catheter which is implanted into the venous outflow of the heart, whereby Gambro's membrane technology is used to monitor biochemical processes which are predicative of infarcts and heart failure. The system is cleared for up to 48 hours of continuous monitoring and intended for intensive care use. "We have tested several types of membranes but Gambro's is the only type we have found that can stay in blood for several days with full functionality and without any signs of complications." says Henrik Falkén, Managing Director of Dipylon.

For further information please contact:

Maria Lundbäck, Gambro, Acting Head of Corporate Communications, tel. +46 705 13 65 34

Patrick Greatrex, Gambro, Vice President Business Development, Tel: +46 733 16 94 69

Måns Alfvén, CEO, Dipylon Medical AB, Tel: +46 707 81 21 99

*Dipylon Medical AB has developed a unique new system for monitoring patients in connection with cardiac surgery. The system measures lactate directly in the venous outflow from the heart, thus providing a very early indication of any complications. As a result of the early detection of potentially life-threatening complications, such as post-operative infarction, treatment can be initiated before permanent damage is caused. This will improve the patients' prospects of survival and reduce healthcare costs. The company was founded in 2006 by Professor Anders Franco-Cereceda and Associate Professor Jan Liska, thoracic surgeons at Karolinska University Hospital.*

[www.dipylonmedical.se](http://www.dipylonmedical.se)

*Gambro is a global medical technology company and a leader in developing, manufacturing and supplying products, therapies and services for In-center Care and Self Care hemodialysis, Peritoneal Dialysis, Renal Intensive Care and Hepatic Care. Gambro was founded in 1964 and has more than 8,000 employees, production facilities in 9 countries, sales subsidiaries in more than 40 and sales in more than 100 countries.*

**Gambro**  
Regeringsgatan 29  
PO Box 7373  
SE-103 91 Stockholm  
Sweden  
Tel +46 8 613 65 00  
Fax +46 8 611 28 30  
[www.gambro.com](http://www.gambro.com)